Cholangiocarcinoma – Basic Information

Go back

Cholangiocarcinoma is a rare and aggressive cancer that forms in the bile ducts, the slender tubes that carry digestive fluid from the liver and gallbladder to the small intestine. This disease often goes unnoticed until it reaches advanced stages, making it challenging to treat. Understanding the nature of this cancer, its warning signs, and the factors that increase risk can help patients and families navigate the journey ahead with greater awareness and support.

Understanding How Common Cholangiocarcinoma Is

Cholangiocarcinoma is considered a rare form of cancer, though its occurrence has been gradually increasing in recent years. In the United States, approximately 8,000 people are diagnosed with this disease annually[2]. This cancer most commonly affects older adults, with the majority of cases appearing in people around age 70[2]. However, it’s important to note that cholangiocarcinoma can develop at any age, even though it predominantly strikes those over 50[1].

The global distribution of cholangiocarcinoma shows interesting geographical patterns. While it remains uncommon in Western countries, the disease is significantly more prevalent in Southeast Asia[2][9]. This higher rate in Asian regions is largely connected to infections caused by liver flukes, particularly a parasite called the Chinese liver fluke. In these endemic areas, chronic infection with this parasite creates ongoing inflammation in the bile ducts, which can eventually lead to cancer development. The condition associated with this parasite, called clonorchiasis (a long-term parasitic infection), represents a major risk factor for cholangiocarcinoma in affected populations[2].

Understanding these patterns helps healthcare providers remain vigilant for early signs of the disease, especially in populations known to be at higher risk.

What Causes This Cancer

The exact cause of cholangiocarcinoma remains unclear to medical experts. However, research has identified that conditions causing long-term inflammation in the bile ducts appear to play a significant role in cancer development[2][13]. When inflammation persists over time, it causes repeated damage to the cells lining the bile ducts. This ongoing damage can lead to changes in the cell’s DNA (the genetic material that contains instructions telling cells how to behave). When DNA becomes damaged, cells may begin to grow and divide abnormally, potentially forming tumors[2].

In many cases, cholangiocarcinoma develops without any clear trigger and without genetic predisposition passed down through families. The disease frequently arises spontaneously, making it difficult to predict or prevent in most individuals[3].

In regions where liver fluke infections are common, the route to cancer is more clearly understood. The parasite creates chronic irritation and inflammation in the biliary system, creating an environment where cancer cells can develop over many years of sustained damage[9].

Groups and Conditions That Increase Risk

Several health conditions and circumstances can increase a person’s chance of developing cholangiocarcinoma. Understanding these risk factors helps identify individuals who may benefit from closer monitoring.

Certain liver and bile duct diseases create an environment more favorable for cancer development. Primary sclerosing cholangitis (a condition causing long-term inflammation and scarring of bile ducts) is one of the most significant risk factors. People with inflammatory bowel diseases such as ulcerative colitis or Crohn’s disease also face increased risk[6]. Chronic liver conditions including hepatitis (inflammation of the liver often caused by viruses) and cirrhosis (severe scarring of the liver) can also predispose individuals to bile duct cancer[2][6].

Structural abnormalities in the biliary system also contribute to risk. Choledochal cysts (abnormal enlargements of bile ducts present from birth) and problems with bile stones or bile duct infections can create conditions favoring cancer development[6].

Lifestyle and demographic factors matter as well. Older age naturally increases risk, as the disease predominantly affects those in their 70s. Weighing more than is healthy and having a family member previously diagnosed with cholangiocarcinoma also elevate the chances of developing this cancer[6].

⚠️ Important
Having one or more risk factors does not mean a person will definitely develop cholangiocarcinoma. Many people with risk factors never develop the disease, while others without known risk factors may still be diagnosed. These factors simply indicate increased probability rather than certainty.

Recognizing the Warning Signs

One of the most challenging aspects of cholangiocarcinoma is that symptoms typically don’t appear until the cancer has grown large enough to block a bile duct. This delay in symptom onset means the disease often reaches advanced stages before anyone realizes something is wrong[2][13].

The most noticeable symptom is jaundice, which occurs when bile cannot flow normally and builds up in the body. Jaundice causes the skin and the whites of the eyes to turn a yellowish color. Along with this color change, people often notice their urine becoming unusually dark while their stools turn pale or clay-colored[2][4][6].

Many people with bile duct cancer experience severe itching of the skin, which occurs because substances that would normally be eliminated in bile accumulate in the body[2][4]. Some individuals notice their stools becoming greasy in appearance[6].

Pain in the abdomen represents another common symptom, though cholangiocarcinoma isn’t usually painful in its early stages. As tumors grow larger, they can cause discomfort that may concentrate on the right side of the abdomen, underneath the ribs. This pain might also spread to other regions of the belly or extend into the back[2][4].

General symptoms affecting overall wellbeing include unexplained weight loss, loss of appetite, persistent fatigue, fever, and episodes of nausea and vomiting[2][4][6]. These symptoms can occur with many different conditions, not just bile duct cancer, which makes diagnosis more complex. Anyone experiencing unusual abdominal pain or these combinations of symptoms should consult a healthcare provider to determine the underlying cause.

Steps to Lower Your Risk

While there are no guaranteed methods to prevent cholangiocarcinoma, certain actions may help reduce risk, particularly in regions where liver fluke infections are common. In endemic areas, taking the anthelmintic medication praziquantel (a drug that eliminates parasitic worms) can decrease the risk of developing cancer from liver flukes[9]. However, reinfection with the parasite remains common in these regions, and future vaccination strategies may offer more effective long-term protection[9].

Managing underlying conditions that increase risk represents another preventive approach. People with inflammatory bowel disease, chronic liver conditions, or primary sclerosing cholangitis should work closely with their healthcare providers to control these conditions and monitor for any early signs of bile duct changes.

There are currently no routine screening tests recommended for detecting cholangiocarcinoma before symptoms appear in the general population[4]. This absence of screening makes symptom awareness and prompt medical attention even more crucial when warning signs do develop.

How the Disease Changes Body Function

To understand how cholangiocarcinoma affects the body, it helps to know what bile ducts normally do. Bile ducts form a network of tubes connecting the liver, gallbladder, and small intestine. These tubes carry bile, a yellow-green digestive fluid produced by the liver. Bile helps break down fats during digestion. The liver produces bile continuously, which flows through small ducts that merge into larger ones. Some bile travels to the gallbladder for storage, and when you eat, the gallbladder releases bile into the small intestine to aid in digesting food[1][4].

Cholangiocarcinoma disrupts this process by forming tumors in the bile duct walls. More than 95 percent of cholangiocarcinomas are adenocarcinomas (cancers that begin in gland-like cells that line organs and produce fluids)[3]. As cancer cells multiply, they create masses that can narrow or completely block the ducts. When bile cannot flow properly, it backs up into the liver and eventually enters the bloodstream, causing the yellowing of skin and eyes seen in jaundice.

The location of the cancer determines its classification and impacts how it affects the body. Intrahepatic cholangiocarcinoma develops in the small bile ducts inside the liver itself. Perihilar cholangiocarcinoma (also called a Klatskin tumor) forms at the hilum, the area just outside the liver where smaller bile ducts join together. This represents the most common type of bile duct cancer. Distal cholangiocarcinoma occurs in the portion of the bile duct closest to the small intestine[1][2][4].

Perihilar and distal cholangiocarcinoma are together called extrahepatic bile duct cancers because they form outside the liver rather than within it[2][4].

Cholangiocarcinoma is an aggressive cancer, meaning it tends to grow and spread quickly. By the time most people receive a diagnosis, the cancer has already spread beyond the bile ducts themselves. Nearly 75 percent of patients have cancer that cannot be surgically removed or has already spread to distant parts of the body when first detected[3]. This advanced stage at diagnosis makes cholangiocarcinoma particularly difficult to treat and contributes to the generally poor outlook for recovery[2].

As the disease progresses, the cancer can invade surrounding tissues and organs. It can also spread through the lymphatic system and bloodstream to create metastatic tumors (secondary cancers) in other parts of the body[2].

⚠️ Important
Cholangiocarcinoma research continues to advance, with scientists investigating the molecular mechanisms underlying the disease. Recent studies have identified specific genetic changes that drive cancer development in some patients, leading to new targeted therapies that show promise in improving outcomes for people facing this challenging diagnosis.

Ongoing Clinical Trials on Cholangiocarcinoma

  • Study on the Impact of [18F]-AlF-FAPI-74, Glucagon, and Hyoscine Butylbromide in Patients with Resectable Biliary Tract Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    The Netherlands
  • Study on Durvalumab, Cisplatin, and Gemcitabine for Patients with Extrahepatic Cholangiocarcinoma

    Recruiting

    1 1 1
    Investigated diseases:
    Germany
  • Study of Futibatinib for Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Portugal Spain
  • Study on Hilar Cholangiocarcinoma Treatment Using Porfimer Sodium and Foscan for Patients with Bile Duct Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Germany
  • Study on Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Ireland Italy +4
  • Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

    Not yet recruiting

    1 1 1 1
    France
  • Study on 68Ga-FAPI-46 PET Imaging for Patients with Gastrointestinal Cancers

    Not yet recruiting

    1 1 1
    Germany
  • Study of Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany The Netherlands Sweden
  • Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    France
  • Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Austria Belgium France Germany Italy The Netherlands +2

References

https://www.mayoclinic.org/diseases-conditions/cholangiocarcinoma/symptoms-causes/syc-20352408

https://my.clevelandclinic.org/health/diseases/21524-cholangiocarcinoma

https://www.ncbi.nlm.nih.gov/books/NBK560708/

https://www.cancer.gov/types/liver/bile-duct-cancer

https://surgicaloncology.ucsf.edu/condition/bile-duct-cancer-cholangiocarcinoma

https://www.oncolink.org/cancers/gastrointestinal/cholangiocarcinoma/cholangiocarcinoma-the-basics

https://www.mskcc.org/cancer-care/types/bile-duct-cancer-cholangiocarcinoma/types

https://willenbringlab.ucsf.edu/condition/bile-duct-cancer-cholangiocarcinoma

https://www.nature.com/articles/s41572-021-00300-2

https://www.mayoclinic.org/diseases-conditions/cholangiocarcinoma/diagnosis-treatment/drc-20352413

https://www.cancer.gov/types/liver/bile-duct-cancer/treatment

https://pmc.ncbi.nlm.nih.gov/articles/PMC8771522/

https://my.clevelandclinic.org/health/diseases/21524-cholangiocarcinoma

https://www.cholangiocarcinoma.org/treatment-options/

https://www.mskcc.org/cancer-care/types/bile-duct-cancer-cholangiocarcinoma/treatment

https://www.mdanderson.org/cancer-types/bile-duct-cancer/bile-duct-cancer-treatment.html

https://www.cancerresearchuk.org/about-cancer/bile-duct-cancer/living-with/advanced

https://www.cholangiocarcinoma.org/newly-diagnosed/

https://www.mayoclinic.org/diseases-conditions/cholangiocarcinoma/diagnosis-treatment/drc-20352413

https://health.clevelandclinic.org/living-with-cholangiocarcinoma-bile-duct-cancer

https://liverfoundation.org/resource-center/videos/lisas-story/

https://www.cancerresearchuk.org/about-cancer/bile-duct-cancer/living-with/coping

https://conquer-magazine.com/issues/special-issues/cholangiocarcinoma-your-patient-journey

https://www.cancer.org/cancer/types/bile-duct-cancer/treating/based-on-situation.html

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

FAQ

Can cholangiocarcinoma be detected before symptoms appear?

Currently, there are no routine screening tests available for cholangiocarcinoma in people without symptoms. This makes early detection challenging, as the disease typically doesn’t cause noticeable problems until it has grown large enough to block bile flow. People with known risk factors should discuss monitoring options with their healthcare providers.

Why does bile duct cancer cause itchy skin?

When bile ducts become blocked by cancer, bile cannot flow normally and substances within it accumulate in the bloodstream. These bile components deposit in the skin, triggering intense itching that can affect the entire body. This symptom, along with jaundice, often prompts people to seek medical attention.

Is cholangiocarcinoma hereditary?

Cholangiocarcinoma usually develops without genetic predisposition passed down through families. While having a family member with the disease slightly increases risk, the cancer most often arises spontaneously without inherited genetic causes. Most cases occur in people with no family history of the disease.

What is the difference between intrahepatic and extrahepatic cholangiocarcinoma?

Intrahepatic cholangiocarcinoma forms within the small bile ducts inside the liver, while extrahepatic cholangiocarcinoma develops in bile ducts outside the liver. Extrahepatic types are further divided into perihilar (near where ducts exit the liver) and distal (closer to the small intestine). Each type has distinct characteristics and treatment approaches.

Can lifestyle changes reduce the risk of developing cholangiocarcinoma?

While no lifestyle changes can guarantee prevention, maintaining a healthy weight and managing chronic liver conditions may help reduce risk. In areas where liver flukes are common, avoiding raw or undercooked fish can prevent parasitic infection. People with inflammatory bowel disease or primary sclerosing cholangitis should work closely with doctors to monitor their condition.

🎯 Key takeaways

  • Cholangiocarcinoma is a rare, aggressive cancer affecting about 8,000 Americans yearly, most commonly appearing in people around age 70.
  • The disease is much more common in Southeast Asia due to liver fluke parasites consumed through raw fish, creating a preventable risk factor through dietary changes.
  • Symptoms typically don’t appear until cancer blocks bile flow, causing yellowing of skin and eyes, dark urine, pale stools, severe itching, and abdominal pain.
  • Chronic inflammation from conditions like primary sclerosing cholangitis, inflammatory bowel disease, hepatitis, and cirrhosis significantly increases cancer risk.
  • Nearly three-quarters of patients have advanced disease at diagnosis because early-stage cholangiocarcinoma causes no symptoms and no screening tests exist for average-risk individuals.
  • The cancer forms in three distinct locations—inside the liver, just outside where ducts merge, or near the small intestine—each requiring different treatment strategies.
  • Recent genetic discoveries have revealed specific DNA changes in some cholangiocarcinomas, leading to new targeted therapies that offer hope for improved outcomes.
  • Despite its challenges, ongoing research into the molecular mechanisms of cholangiocarcinoma continues to advance, with scientists developing better treatments and understanding of this complex disease.